Ewch i’r prif gynnwys

Grŵp Therapïau Uwch

The Advanced Therapies Group, within the School of Dentistry, is involved in using our knowledge of the molecular and cellular control of human disease processes to inform the design, development and testing of novel polymer therapeutics in the prevention and treatment of difficult to treat, often life-threatening infections.  The work of the group is focused on polymer therapies derived from nature in applied research, and their use in a range of applications in the prevention and treatment of human disease.

A significant area of our research is employed in investigating a low molecular weight alginate (OligoG CF-5/20), which has been shown to enhance the activity of conventional antibiotics against multi-drug resistant Gram-negative bacteria and biofilms, for example, Pseudomonas and Burkholderia spp. which complicate the treatment of cystic fibrosis.  This work is now being broadened to tailor the alginate to its maximum potential therapeutic effect.  The group is also characterising microbial growth on novel nanocellulose wound dressing materials for chronic wound applications.

Key achievements have been in developing new strategies to specifically target otherwise undeliverable proteins, peptides and drugs to sites of disease by the chemical bonding of safe, water-soluble natural polymers extracted from plants and animals.  These so-called "nanomedicines" are capable of reducing the side effects of conventional drugs by 'enveloping' them in a polymer 'coat', so that once they reach the site of disease, they can be triggered to release the drug by the body's own proteins.  Thus, patients require lower doses and less frequent dosing.


Alginate Nanomedicines

Research here, as part of a multi-national collaboration with AlgiPharma AS, has involved development of polymer therapies based on the biopolymer alginate, derived from seaweed.  The first product, currently in Phase IIb clinical trials is OligoG, a low molecular weight alginate oligosaccharide.  We first demonstrated in 2010 how these oligomeric structures were able to potentiate antibiotics (by up to 500-fold) against a range of multi-drug resistant (MDR) human pathogens and inhibit biofilm formation.  Subsequent research sponsored by the EU, US Department of Defence, Cystic Fibrosis Foundation and the EU Eurostars Programme has led to the optimisation of the delivery of OligoG as an inhalation therapy for cystic fibrosis and in the treatment of patients with life-threatening infections of MDR bacteria, where work is ongoing in the group.

Tailored OligoG

The Advanced Therapies Group are a key part of a four year £5.4 million research grant from the Norwegian Research Council in collaboration with AlgiPharma AS, SINTEF and NTNU, Norway looking into the development of novel alginate oligomers for clinical use.  This exciting programme is a vital component of an International consortium to investigate microbial sources of raw material for the formulation of new prevention strategies and treatments for persistent, difficult to treat infections for AlgiPharma's alginate technology programme.


This project is involved in the development of bio-compatible cellulose nanomaterials (derived from tree pulp) with innovative, functional properties for advanced wound healing applications in conjunction with the Paper Research Institute (PFI), Trondheim.  The ability of these nanofibres (from renewable sources) to interact with complementary polymers and form novel material structures for use in applications as diverse as wound dressings, graft scaffolds for tissue engineering and bio-sensing in a range of human diseases forms the basis of our ongoing research.

See images: figure 1

Polymer Conjugates

Our ongoing research is investigating novel combinations of polymers and peptides for the treatment of chronic inflammation and infection, and novel polymer-growth factor conjugates as adjunctives to stem cell therapy.  Successful translation of this research has wide applications, not only in dentistry (e.g. maxillofacial trauma, periodontitis), but shows potential for use in an extensive range of diseases (e.g. diabetic foot ulcers, cystic fibrosis, spinal cord injury).

See images: figure 2

Selected publications

There was an error trying to connect to API. Please try again later. HTTP Code: 301

Current grants

Current grantsFunding
Research Council of Norway (2015-2018)BIA-Alginates£3.174,600
Research Council of Norway (2015-2018)Tailored OligoG£1,032,830
Research Council of Norway (2012-2016)Nanoheal£1,082,480
QBiotics Ltd (2012-2015)EBC-46£59,162
MRC New Investigator Research Grant (2016-2019)Accumulation and nephrotoxicity of dextrin-colistin conjugates£399,982

Clinical trials

Lead researcher

David Thomas

Yr Athro Dave W Thomas

Cyfarwyddwr y Rhaglen Mewnblaniadau Deintyddol, Cyfarwyddwr Rhaglen Hyfforddiant Academaidd Integredig Cymru mewn Deintyddiaeth, Ysgol Deintyddiaeth, Arweinydd Arloesedd Sefydliadau Ymchwil y Brifysgol

+44 (0)29 207 44873

Academic staff

Elaine Ferguson

Dr Elaine Ferguson

Uwch ddarlithydd mewn Therapiwteg Polymer

+44 (0)2922 510663
Katja Hill

Dr Katja Hill

Cymrawd Ymchwil Ôl-Ddoethurol

+44 (0)29 2074 4252

Dr Lydia Powell

Research Associate


Dr Mathieu Varache

Research Associate


Postgraduate students